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Extended Abstract
Introduction: Breast cancer is the second most common malig-
nancy in women .Worldwide, cancer incidence and related deaths
of cancer are consistently rising. Breast cancer is a heterogenic dis-
ease which a collection of diseases each with variability in genetics
factors, distinct histopathological characteristic and different prog-
nostic outcomes. According to the International Agency for Research
on Cancer, new cases of cancer reported increased from 12.7 million
in 2008 to 14.1 million in 2012 and responsible for 23% of total can-
cer cases and 14% of all cancer related mortalities. In Iran breast can-
cer is the most common cancer as well, 24.4% of all cancers and
between 2005e2006, its incidence was 17.8%. Breast cancer affects
the Iranian women at least a decade earlier than women in developed
countries, most of the new diagnosed cases are in the age of 40e49
years old. Most cancer deaths are due to metastasis. Metastasis is a
complicated process involving altered cell adhesion, degradation of
the basement membrane, survival, migration, angiogenesis, immune
escape mechanisms, proliferation in target organs and constitutes
the second tumor.
Like other cancers, metastasis is the main reason which causes the
treatment failure and death in breast cancer patients. Metastatic breast
cancer (MBC) is a major therapeutic challenge both in the first indi-
cation of breast cancer and recurrence after treatment in the early
stage of disease. Breast cancer mostly metastasize lymph nodes,
bones, lungs, liver and brain. Mean survival of women with meta-
static breast cancer is about 3 years. Therefore there is a critical con-
cern to identify prognostic markers of metastatic disease and targets
for treatment. MiRNAs play important roles in many physiological
procedures and they are recognized as endogenous regulators of
gene expression. These small RNAs are able to controlling gene
expression by repressing translation and transcription. Loss or ampli-
fication of miRNA genes has been reported in almost all cancers, they
can act as tumor suppressors or have oncogenic functions, and change
in patterns of miRNA expression can influence cell cycle. Some
microRNAs regulate proliferation, differentiation and apoptosis.
These are the major features of cancer initiation, progression, inva-
sion and metastases.
MiR-137 plays critical roles in the nervous system, an increase in
its expression is essential for neuronal differentiation while its
decrease in its level of expression is observed in gliomagenesis.
MiR-137expression is inhibited via promoter hypermethylation in
colorectal cancer, oral cancer and gastric cancer. MiR-137 targets
nuclear receptor Estrogen-Related Receptor Alpha (ERRa). ERRa is
considered to be an important part of breast cancer signaling pathway1 Mahdieh Daliri Ghouchan Atigh and Atieh Eslahi contributed equally to
this work.and over-expression in breast tumor can be proposed as a prognostic
factor of poor clinical outcome.
Method: Tissue samples of 60 breast cancer patients that had
mastectomy surgery were collected. From these 60 patients 30 of
them had primary tumors and other had metastatic breast cancer.
Metastatic tissue samples were collected from axillary lymph node.
This study design was approved by local ethics committee of Mash-
had University of Medical Sciences and all of patients signed
informed consent. None of patients recruited in this study had under-
gone preoperative chemotherapy or radiotherapy. Identity of tissue
samples were confirmed by pathologist. Samples were snapped frozen
and stored in -80C until use.
RNA extraction and quantitative real-time PCR: RNA extrac-
tions of samples were performed with Hybrid-R miRNA isolation kit
(GnenAll, South Korea). Total cDNA synthesis was performed by
using MiScript II RT kit (Qiagen, Germany) and in order to confirm
appropriate cDNA synthesis, PCR reaction was also done for
GAPDH. Finally the expression of microRNA-137 was explored
using SyberGreen I based miScript Precursor Assays kit (Qiagen,
Germany) and Prime Q-Mastermix (Amplicon, Denmark) in a Ste-
pOne RealTime PCR system (ABI, USA).
All reactions were performed as triplicate. Gene expression
changes were calculated using DDCt method. DDCt method is a con-
venient way to analyze the gene expression changes in case control
studies.
Results: Comparative Real-time PCR method was implemented
in all 60 patient samples. Results showed that Mir-137 expression
was increased up to 7 times in metastatic tissue samples in compare
with primary tumors (Figure 1). Statistical analysis revealed that
these changes were significant.
Conclusion: The current gold standard for breast cancer screening
and diagnosis is mammography technique. miRNAs play a role in
oncogenesis, metastasis and resistance to various therapies in cancer.
Mir-137 may be used as screening and diagnostic biomarkers for
existence of metastatic breast cancer foci.
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Fig. 1. Levels of Mir-137 expression in primary and metastatic tumors.
